OverviewSuggest Edit

Pressure BioSciences, Inc. (PBI), a life sciences company, engages in the research, development, and commercialization of sample preparation system. It focuses on the development of a platform technology, called pressure cycling technology (PCT) that uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The Company offers Barocycler instrument and an internally developed disposable PULSE (Pressure Used to Lyse Samples for Extraction) Tubes, which together make up the PCT sample preparation system.

TypePublic
Founded2004
HQEaston, US
Websitepressurebiosciences.com

Latest Updates

Employees (est.) (Dec 2018)17(+22%)
Revenue (FY, 2018)$2.5 M(+10%)
Share Price (Oct 2017)$3.9 (-2%)

Key People/Management at Pressure BioSciences

Richard T. Schumacher

Richard T. Schumacher

President, Chief Executive Officer and Director
Edmund Ting

Edmund Ting

Senior Vice President of Engineering
Nathan P. Lawrence

Nathan P. Lawrence

Vice President of Marketing and Sales
Alexander Lazarev

Alexander Lazarev

Vice President of Research and Development
Joseph L. Damasio

Joseph L. Damasio

Vice President of Finance and Chief Financial Officer
Show more

Pressure BioSciences Office Locations

Pressure BioSciences has offices in Easton and Medford
Easton, US (HQ)
14 Norfolk Ave, South Easton
Medford, US
200 Boston Ave #1950
Show all (2)

Pressure BioSciences Financials and Metrics

Pressure BioSciences Revenue

Pressure BioSciences's revenue was reported to be $2.46 m in FY, 2018
USD

Revenue (Q2, 2019)

518.7k

Gross profit (Q2, 2019)

214.5k

Gross profit margin (Q2, 2019), %

41.4%

Net income (Q2, 2019)

(2.8m)

EBIT (Q2, 2019)

(1.4m)

Market capitalization (8-Oct-2018)

5.0m

Cash (30-Jun-2019)

117.9k

EV

10.9m
Pressure BioSciences's current market capitalization is $5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

987.7k1.2m1.5m1.4m1.8m2.0m2.2m2.5m

Revenue growth, %

10%

Cost of goods sold

609.1k834.0k1.3m1.3m

Gross profit

1.2m1.1m967.1k1.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

190.7k280.4k305.7k324.9k297.9k370.7k357.7k420.8k404.1k307.5k372.5k440.1k413.1k580.3k510.5k511.0k535.3k551.4k540.4k646.1k610.8k639.0k521.8k510.2k518.7k

Cost of goods sold

108.7k175.2k209.8k221.7k243.1k262.9k236.0k287.3k328.7k324.8k270.0k234.3k309.7k304.2k

Gross profit

189.2k237.9k370.5k288.8k267.9k272.4k315.4k253.1k317.3k286.0k369.0k287.4k200.5k214.5k

Gross profit Margin, %

64%58%64%57%52%51%57%47%49%47%58%55%39%41%
USDY, 2019

EV/EBIT

-7.8 x

EV/CFO

-3.3 x

Debt/Equity

-0.7 x

Debt/Assets

2.7 x

Financial Leverage

-0.3 x
Show all financial metrics

Pressure BioSciences Online and Social Media Presence

Embed Graph

Pressure BioSciences News and Updates

Zacks Small Cap Research Initiates Coverage on Pressure BioSciences, Inc.

SOUTH EASTON, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sci…

Pressure BioSciences Prepares for Growth, Adding Daniel J. Shea as Chief Financial Officer

Shea’s 30-Year Diverse Experience in Acquisitions, Capital Markets, SEC Reporting, and Leading Financial Organizations Bolsters PBI’s Strong Senior Management Team    South Easton, MA - (NewMediaWire) - September 17, 2019 - Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a lead…

Pressure BioSciences Announces Two More Purchase Orders for its Revolutionary BaroShear K45 Processing System for Manufacturing Water-Soluble CBD

Company Forecasts All 12 Systems in Current Build Cycle Will Be Sold by September 30, 2019 and Reiterates Previous Guidance for More Than Doubling of Annual Revenue in 2020  South Easton, MA - (NewMediaWire) - August 22, 2019 - Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a l…

Pressure BioSciences Looks to Disrupt the Life Sciences Sector with Its Novel Technologies

The Company's entry into protein therapeutics and nanoemulsion solutions using breakthrough technologies coupled with its core instruments enable it to provide transformative solutions to the life sciences industry EASTON, PA - (NewMediaWire) - March 29, 2019 - Small Caps Daily recently publish…

NutraFuels, Inc. and Pressure BioSciences, Inc. to Collaborate on the Development of Water-Soluble Nanoemulsion-based Nutraceuticals

Coconut Creek, FL, Jan. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- NutraFuels, Inc. (OTCQB: NTFU) (NTFU) and Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI) (together, the “Companies”) today announced a collaboration to advance the development of a new generation of health and wellness nutrac…

Pressure BioSciences Frequently Asked Questions

  • When was Pressure BioSciences founded?

    Pressure BioSciences was founded in 2004.

  • Who are Pressure BioSciences key executives?

    Pressure BioSciences's key executives are Richard T. Schumacher, Edmund Ting and Nathan P. Lawrence.

  • How many employees does Pressure BioSciences have?

    Pressure BioSciences has 17 employees.

  • What is Pressure BioSciences revenue?

    Latest Pressure BioSciences annual revenue is $2.5 m.

  • What is Pressure BioSciences revenue per employee?

    Latest Pressure BioSciences revenue per employee is $144.6 k.

  • Who are Pressure BioSciences competitors?

    Competitors of Pressure BioSciences include ResMed, Avinger and SteadyMed Therapeutics.

  • Where is Pressure BioSciences headquarters?

    Pressure BioSciences headquarters is located at 14 Norfolk Ave, South Easton, Easton.

  • Where are Pressure BioSciences offices?

    Pressure BioSciences has offices in Easton and Medford.

  • How many offices does Pressure BioSciences have?

    Pressure BioSciences has 2 offices.